Pair Name | Berbamine, Cisplatin | ||
Phytochemical Name | Berbamine (PubChem CID: 275182 ) | ||
Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Berbamine, Cisplatin | |||
Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
Biological Phenomena | Induction-->Necroptosis | |||
Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
Up-regulation | Cleavage | CASP8 | hsa841 | |
Up-regulation | Phosphorylation | MLKL | hsa197259 | |
Up-regulation | Phosphorylation | RIPK3 | hsa11035 | |
In Vitro Model | OVCAR-3 | High grade ovarian serous adenocarcinoma | Homo sapiens (Human) | CVCL_0465 |
Result | This study proposed that the combination therapy of BBR and DDP markedly enhanced more ovarian cancer cell death by inducing apoptosis and necroptosis, which may improve the anticancer effect of chemotherapy drugs. The apoptosis involved the caspase-dependent pathway, while the necroptosis involved the activation of the RIPK3-MLKL pathway. We hope our findings might provide a new insight for the potential of BBR as a therapeutic agent in the treatment of ovarian cancer. |
Pair Name | Berbamine, Cisplatin | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Down-regulation | Expression | BCL2 | hsa596 | |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Up-regulation | Expression | CYCS | hsa54205 | |
Up-regulation | Expression | MAP1LC3A | hsa84557 | |
Up-regulation | Expression | MAP1LC3B | hsa81631 | |
Up-regulation | Phosphorylation | MAPK14 | hsa1432 | |
Up-regulation | Phosphorylation | MAPK8 | hsa5599 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
Up-regulation | Expression | SQSTM1 | hsa8878 | |
In Vitro Model | NCI-H1299 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0060 |
NCI-H1975 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_1511 | |
In Vivo Model | Cells were injected into the axilla of nude mice at the amount of 5×10⁷ cells/nude mice, and the tumor formation of the transplanted tumor was observed and measured daily. | |||
Result | These findings indicate that Ber might be a promising adjuvant for enhancing the cancer cell killing effect of chemotherapy via the inhibition of autophagy. In this process, Nox2 might be a significant mediator of Ber-induced aberrant lysosomal acidification. |
No. | Title | Href |
---|---|---|
1 | Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells. Biol Res. 2019 Jul 18;52(1):37. doi: 10.1186/s40659-019-0243-6. | Click |
2 | Berbamine Hydrochloride inhibits lysosomal acidification by activating Nox2 to potentiate chemotherapy-induced apoptosis via the ROS-MAPK pathway in human lung carcinoma cells. Cell Biol Toxicol. 2023 Aug;39(4):1297-1317. doi: 10.1007/s10565-022-09756-8. | Click |